Meeting
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
Authors
Sebastian Grosicki
Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland
Sebastian Grosicki , Su-Peng Yeh , Jeffrey S.Y. Huang , Ja Min Byun , Christine DiRienzo , Andrea Viqueira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05623020
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8065)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8065
Abstract #
TPS8065
Poster Bd #
56a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
First Author: Sebastian Grosicki
Poster
2019 ASCO Annual Meeting
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).
First Author: Pieter Sonneveld
Poster
2019 ASCO Annual Meeting
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.
First Author: Saad Zafar Usmani
Poster
2017 ASCO Annual Meeting
Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
First Author: Nizar J. Bahlis